Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
1.450
-0.040 (-2.68%)
Nov 21, 2024, 11:26 AM EST - Market open
LIXT Employees
As of December 31, 2023, Lixte Biotechnology Holdings had 4 total employees, including 3 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,000,132
Market Cap
3.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 231 |
| NovaBay Pharmaceuticals | 26 |
| Azitra | 10 |
| Chromocell Therapeutics | 8 |
| Artelo Biosciences | 6 |
| Synaptogenix | 5 |
| Titan Pharmaceuticals | 4 |
| Tharimmune | 3 |
LIXT News
- 2 months ago - LIXTE Receives U.S. Patent Issue Notification for Immune Oncology - GlobeNewsWire
- 3 months ago - First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Provides Update On Recent Activities and Developments - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Holdings to Present at Two Investor Conferences - GlobeNewsWire
- 3 months ago - Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event - Accesswire
- 5 months ago - LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial - GlobeNewsWire
- 5 months ago - LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial - GlobeNewsWire
- 6 months ago - Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System - GlobeNewsWire